What is it about?
This study aims to introduce an innovative multi-step pipeline for automatic tumor-stroma ratio (TSR) quantification as a potential prognostic marker for pancreatic cancer, addressing the limitations of existing staging systems and the lack of commonly used prognostic biomarkers.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Pancreatic ductal adenocarcinoma (PDAC), usually referred as pancreatic cancer is now the seventh leading cause of cancer-related deaths worldwide and will soon become the second leading cause of cancer-related death in Western society. patient management for PDAC is mainly based on the well-known TNM staging system but despite being widely used, it is considered unreliable as patients with the same TNM stage often present different prognosis, therefore there is an urge to develop new reliable biomarkers able to correctly stratify patients to assess the correct treatment.
Perspectives
I hope this article helps other researchers in focussing their research on pancreatic cancer, as over the past 20 years there were no significant steps in this field.
Pierpaolo Vendittelli
Radboud Universiteit
Read the Original
This page is a summary of: Automatic quantification of tumor-stroma ratio as a prognostic marker for pancreatic cancer, PLoS ONE, May 2024, PLOS,
DOI: 10.1371/journal.pone.0301969.
You can read the full text:
Resources
Contributors
The following have contributed to this page
